ADRB2 polymorphisms and budesonide/formoterol responses in COPD.

Area of Science:

• Pharmacogenetics
• Respiratory Medicine
• Genetics

Background:

• Long-acting beta-2 adrenergic agonists are crucial for COPD management.
• The role of ADRB2 gene polymorphisms in treatment response requires further investigation in long-term COPD trials.
• Specifically, the ADRB2 Gly16Arg polymorphism's impact on formoterol therapy is not well-established.

Purpose of the Study:

• To evaluate the influence of the ADRB2 Gly16Arg polymorphism on therapeutic responses to formoterol.
• To assess the impact of this polymorphism when formoterol is used alone or combined with budesonide in COPD patients.
• To analyze effects on lung function, exacerbations, and adverse events.

Main Methods:

• Analysis of data from two independent, large-scale, randomized, placebo-controlled trials (12-month and 6-month duration).
• Patients with moderate to very severe COPD received various combinations of budesonide and formoterol via metered-dose inhaler or dry powder inhaler.
• Pharmacogenetic analysis focused on the ADRB2 Gly16Arg polymorphism and its correlation with predose and postdose FEV1, exacerbations, and adverse events.

Main Results:

• No significant interaction was found between the ADRB2 Gly16Arg genotype and treatment response for predose or postdose FEV1 in 2,866 patients.
• The incidence of COPD exacerbations was low and comparable across different genotypes in the active treatment groups.
• Adverse event rates were similar among patients with different Gly16Arg genotypes for each treatment regimen.

Conclusions:

• The ADRB2 Gly16Arg genotype does not modify therapeutic response to long-term treatment with formoterol alone or in combination with budesonide.
• These findings suggest that current treatment strategies with budesonide/formoterol are effective regardless of ADRB2 Gly16Arg genotype in COPD patients.
• The study provides robust evidence from large independent pharmacogenetic studies in COPD.